The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Highlights in sickle cell disease from ASH 2025: hydroxyurea in pregnancy, gene editing, and more
In this video, Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, shares his highlights in sickle cell disease (SCD) from the ASH 2025 meeting. Dr Hanna mentions promising data on the safety of hydroxyurea in pregnant patients and expresses his excitement about novel gene editing techniques presented at the event. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
